Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine extended-release for ADHD in children and adolescents (Phase 3, randomized, double-blind, placebo-controlled)
ChiCTR2500107639Phase 3Completed
- Sponsor
- Beijing Anding Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Guanfacine extended-release with Placebo (2 arms). Primary endpoint: Change in ADHD-RS-IV parent total score. Started Aug 2025; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ChiCTR2500107639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107639.